Lung cancer is the leading cause of cancer-related death in the world. Prior to the era of targeted therapy, platinum-based doublet chemotherapy was the first-line therapy of choice for patients with metastatic non-small-cell lung cancer (NSCLC). The availability of agents that target epidermal growth factor receptor (EGFR)-tyrosine kinase, as well as inhibitors against anaplastic lymphoma kinase (ALK ) gene rearrangement or ROS-1 gene rearrangement product, has provided promising clinical benefits in specific subpopulations of NSCLC. At present, only first-generation EGFR-tyrosine kinase inhibitors (TKIs) (erlotinib and gefitinib) are available for clinical use. Second-generation irreversible EGFR-TKIs, such as afatinib, are still in clinical trials. In current clinical practice, EGFR-TKI is the first-line treatment of choice for metastatic NSCLC patients with tumor EGFR mutation or as salvage therapy in NSCLC patients who received systemic chemotherapy previously. Platinum-based doublet chemotherapy continues to be the standard of care for those treatment-naïve patients with EGFR wild -type tumor or unknown EGFR status. Even though all investigators agree with the use of EGFR-TKI as the first-line treatment in tumor EGFRmutated patients, only 10e30% of NSCLC patients have mutated EGFR, and there was no obvious survival difference when EGFR-TKIs were used in a second-line setting versus a first-line treatment in EGFR-mutated patients. Thus, the molecular complexity of lung cancer emphasizes the need for optimizing treatment by seeking a more personalized approach to care, including searching for driver oncogenes, managing the emergence of resistance and overcoming that resistance, and optimizing the sequence of treatment. Numerous other novel targeted agents are now in clinical development, including new agents targeting novel pathways and those that may have the potential to overcome the limitations or resistance associated with currently available EGFR-TKIs. In this report, we review the clinical data of EGFR-TKIs as moleculartargeted therapies in NSCLC.
Introduction
For patients with metastatic non-small-cell lung cancer (NSCLC), chemotherapy was considered the standard treatment prior to the era of targeted therapy. Although chemotherapy may result in a modest improvement in patient survival, the overall prognosis of these patients remains dismal, and the treatment is relatively nonspecific and toxic in nature. Therefore, new therapeutic strategies are needed urgently.
During the past decade, targeted therapies against NSCLC, especially adenocarcinoma, have exhibited marked achievements, and resulted in improvement in patient survival, either progression-free survival (PFS) or overall survival, and an enhanced quality of life in specific patient populations. 1e5 Several driver oncogenes that contribute to lung cancer progression and metastasis have been identified, and have led to the discovery of several potential molecular targets (Fig. 1) . 1,6e11 Epidermal growth factor receptor (EGFR) and its signal transduction pathway have undergone the most active and advanced research. In this report, we review the clinical data on the use of EGFR-tyrosine kinase inhibitors (TKIs) for molecular-targeted therapies in NSCLC.
EGFR signal transduction pathway
EGFR was the first identified member of a family of receptors known as type I receptor tyrosine kinases (TKs) or ErbB receptors. The binding of ligands to the extracellular domain of the EGFR activates the receptor TK and triggers downstream signaling pathways consisting of a rich multilayered network that permits multiple combinatorial responses. 10, 12 The TK family has two major downstream signaling pathways. One is the RaseRafeMAP kinase pathway. The other important pathway is phosphatidylinositol 3-kinase and the downstream protein-serine/threonine kinase Akt. Another route for signaling is via the stress-activated protein kinase pathway, involving protein kinase C and Jak/Stat. 12 
EGFR inhibition
There are several potential strategies for targeting EGFR.
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Of these approaches, monoclonal antibodies (MoAbs) and TKIs are in the most advanced stages of clinical development. 1, 2, 14 At the level of downstream receptor-dependent signaling pathways, EGFR antibodies and TKIs seem to have similar effects. Both strategies result in an efficient blockade of the main EGFR signal transduction pathways. 13, 15 As a result, anti-EGFR MoAbs and TKIs interfere with a number of key cellular functions regulated by the receptor, which explains their antitumor effects (Fig. 2) . 13, 16, 17 Since the discovery of a high degree of association between tumor EGFR-activated mutations and the efficacy of EGFR-TKIs, the latter have been studied extensively in the treatment of tumor EGFR-mutated NSCLC 1,2 however, anti-EGFR MoAbs has been studied less extensively and successfully used in only one Phase III trial of chemo-naïve NSCLC in combination with doublet chemotherapy. 1, 2, 18 4. First-generation EGFR-TKI Gefitinib (Iressa) and erlotinib (Tarceva) are two firstgeneration EGFR-TKIs that have already been approved for clinical use. These two agents are small molecules that reversibly target EGFR-TK. Their side effects are usually mild to moderate, and consist of a dose-dependent skin rash and diarrhea. In Phase I studies both drugs have resulted in objective responses in heavily pretreated NSCLC patients, when used as single agents. 19, 20 Two randomized Phase II trials [Iressa Dose Evaluation in Advanced Lung Cancer 1 (IDEAL 1) and IDEAL 2] with two dose levels of gefitinib (250 mg/d and 500 mg/d) have been carried out in patients with advanced NSCLC who had progressed after previous chemotherapy. The IDEAL 1 study showed an 18.7% response rate and marked improvement in disease-related symptoms. 21 The 250 mg/d dose was as active Fig. 1 . Histologic and molecular subtypes of NSCLC. Adenocarcinoma is the most common histologic subtype of NSCLC, followed by squamous cell carcinoma (top). Both adenocarcinoma and squamous cell carcinoma can be subdivided further, based on different somatic genomic alterations. as the 500 mg/d dose and had a better toxicity profile. In the IDEAL 2 study tumor objective response rates of 12% and 9% were observed for the 250 mg/d and 500 mg/d groups, respectively. 22 The toxicity profiles of the IDEAL 2 study were similar to those of the IDEAL 1 study. A Phase III randomized study [Iressa Survival Evaluation in Lung Cancer (ISEL)] included 1692 patients who were randomly assigned to receive gefitinib or a placebo. 23 In this study, gefitinib failed to prolong survival statistically compared to the placebo in the overall population (median: 5.6 vs. 5.1 months; p ¼ 0.11). However, a subgroup analysis of East Asian patients showed that those who received gefitinib (n ¼ 235) had superior survival than those who were given a placebo (n ¼ 107) (median: 9.5 vs. 5.5 months; p ¼ 0.012). A Phase III randomized study with a noninferiority design comparing gefitinib with docetaxel in 1433 NSCLC patients who received 1 platinumbased regimens met the predefined noninferiority criterion of overall survival [hazard ratio (HR): 1.020; 95% confidence interval (CI): 0.905e1.150; median survival: 7.6 vs. 8.0 months], suggesting that gefitinib is a valid treatment for pretreated patients having molecular-unselected advanced NSCLC. 24 Erlotinib, an orally available quinazoline, is also a selective EGFR-TKI. It is the first EGFR-TKI to demonstrate an increase in survival of patients with advanced NSCLC in a Phase III randomized trial (BR. 21). 4 In this study, patients treated with erlotinib had a response rate of 8.9% and a statistically significant increase in median (6.7 vs. 4.7 months) and 1-year survival (31% vs. 21%) compared to patients receiving a placebo. 4 Side effects of erlotinib were mild and acceptable, consisting mainly of skin toxicity and diarrhea. Results of a Phase III randomized trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with EGFR wild type tumor have recently been presented at the American Society of Clinical Oncology (ASCO) 2012 annual meeting. 25 
EGFR-TKI combined with chemotherapy
Four large Phase III randomized studies of chemotherapy with or without TKI (gefitinib or erlotinib) in patients with advanced chemo-naïve NSCLC were conducted to determine whether or not gefitinib or erlotinib can enhance the antitumor effect of chemotherapy and thus prolong patient survival more than that with chemotherapy alone (Table 1) . 26e29 In the Iressa NSCLC Trial Assessing Combination Treatment (INTACT) 1 study, the chemotherapy regimen was cisplatin plus gemcitabine. Patients were assigned randomly to chemotherapy plus a placebo, chemotherapy plus gefitinib 250 mg/d, or chemotherapy plus gefitinib 500 mg/d. A total of 1093 patients were enrolled in the study. The results showed no significant differences in response rate, PFS, and overall survival across the three assigned groups. In the INTACT 2 trial, 1037 patients were enrolled in a similarly designed trial, with a chemotherapy regimen consisting of carboplatin and paclitaxel. Again, there were no differences in response rate, PFS, and overall survival across the three groups. Like gefitinib, chemotherapy with/without erlotinib was also used in chemonaïve NSCLC patients [Tarceva Responses in Conjunction with Paclitaxel and Carboplatin (TRIBUTE) and Tarceva Lung Cancer Investigation (TALENT) studies]. These studies also Fig. 2 . EGFR signaling pathway. The processes of ligandereceptor and receptorereceptor interactions lead to the activation of intracellular pathways that regulate cellular survival/apoptosis, proliferative activity, and other functions that together promote malignant behavior. EGFR antibody binds to EGFR and inhibits ligand binding (e.g., EGF). Tyrosine kinase inhibitors (such as gefitinib and erlotinib) bind the intracellular tyrosine kinase domain and block its transduction pathway. EGF ¼ epidermal growth factor; EGFR ¼ epidermal growth factor receptor. failed to show a survival benefit when erlotinib was added to chemotherapy. In the TRIBUTE study, 1059 chemo-naïve advanced NSCLC patients were randomized to receive paclitaxel/carboplatin with or without erlotinib. 28 In the TALENT study, 1172 chemo-naïve advanced NSCLC patients were randomized to receive cisplatin plus gemcitabine with or without erlotinib. 29 The results of these four well-controlled trials, which included a total of 4361 patients, have clearly demonstrated that, in chemo-naïve NSCLC patients, the addition of gefitinib or erlotinib to conventional chemotherapy does not enhance the clinical benefit of chemotherapy alone. Thus, in molecularly unselected NSCLC patients, erlotinib or gefitinib should not be used in combination with cytotoxic chemotherapy as the first-line therapy. 
EGFR mutation
Following the treatment with EGFR-TKIs, examinations of tumor EGFR status by immunohistochemistry, fluorescence in-situ hybridization (FISH), or EGFR mutation status by DNA sequencing were performed and the results were correlated with treatment response and survival status.
1,12,30 EGFR mutation status had its best correlation with treatment efficacy, 1,12,31e33 followed by FISH examinations. 30, 33 In addition to predicting response to EGFR-TKIs, EGFR mutations may also be a prognostic factor. 1,12,34e36 In two large series reports on the epidemiology of EGFR mutations, 37, 38 Shigematsu and Gazdar 37 found that all mutations reported were somatic and occurred within exons 18e21 of the EGFR gene, which encodes part of the intracellular TK domain. Three different types of mutations associated with sensitivity to EGFR-TKIs have been found: (1) in-frame deletions in exon 19, which was the most common mutation and accounted for 46% of all EGFR mutations; (2) missense mutations in exon 18, 20, or 21, which were the second most common mutations and accounted for 41% of all EGFR mutations, particularly the single-nucleotide substitutions L858R in exon 21; and (3) in-frame duplications/insertions in exon 20, accounting for 5% of all mutations. They found that EGFR mutations appear to be associated with sensitivity to EGFR-TKIs, and also with East Asian ethnicity, female gender, no history of smoking, and an adenocarcinoma histology. Murray et al 38 reviewed the data of 12,244 patients, and 3381 somatic EGFR mutations were noted. Exon 19 mutations occurred most frequently (50%), followed by exon 21 (40%), 20 (6%), and 18 (4%) mutations. L858R and delE746-A750 accounted for 32.8% and 24.3% of all mutations, respectively, with 50% of mutations being exon 19 deletions or "deletional insertions". There is a clear association between the presence of mutations and the response to TKI, with exon 19 mutations having the best response rate (70%), followed by exons 21, 18, and 20, with a response rate of around 20% or slightly higher.
The median time to disease progression was around 10 months for EGFR-mutated patients who received EGFR-TKI treatment, with a wide range of differences due to many possible underlying mechanisms, such as coexisting T790M, c-MET amplification, genomic alterations in chromosome 7p, and even a proportion of EGFR wild type tumor cells that could affect PFS.
1,2,39e43 For example, Su et al 39 from Taiwan performed a study of 107 TKI-naïve NSCLC patients with matrixassisted laser desorptioneionization time-of-flight mass spectrometry, and the results showed that T790M might not be a rare event prior to EGFR-TKI treatment in NSCLC patients with EGFR-activating mutations. The pretreatment T790M mutation was associated with shorter PFS when these patients received EGFR-TKI treatment. However, a recent large Phase III trial had an unexpected finding: patients with EGFR compound mutants (exon 19 deletions or L858R plus T790M) attained the maximum benefit (PFS and overall survival) from erlotinib treatment compared to those with exon 19 deletions or L858R alone, 44 suggesting a need for more sensitive assays to detect EGFR compound mutants and for studies of EGFR-TKIs targeting the EGFR T790M mutation. Whole genome sequencing may provide a greater understanding of the genetic factors involved in the differences in survival status. A recent study also showed that an increased expression of the NF-kB inhibitor predicted improved response and survival in EGFR-mutant lung cancer patients treated with EGFR-TKI. 45 The BIM polymorphism is associated with EGFR-TKI intrinsic resistance, and prediction of PFS with EGFR-TKI treatment has also been reported recently. 46 PazAres et al 47 reported a pooled analysis of published studies in patients with EGFR-mutated NSCLC who were treated with chemotherapy or EGFR-TKIs. The results showed that the overall median PFS was 13.2 months with erlotinib, 9.8 months with gefitinib, and 5.9 months with chemotherapy.
Several methods are used to detect EGFR mutations in lung cancer specimens. 48 The sensitivity of direct sequencing is relatively poor and requires more mutant DNA to detect EGFR mutations in specimens (10e25% mutant DNA). Thus, when EGFR mutation was analyzed using the direct DNA sequence method, a 10e20% objective response rate, sometimes even higher in specific clinical populations, was noted in EGFR wild type NSCLC patients.
49e51 High-sensitivity methods, such as the Scorpion amplified refractory mutation system (ARMS) and peptide nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) clamp methods, are more sensitive and able to detect 1% mutant DNA in the specimens.
3,48,52,53 However, direct sequencing can detect new mutations, while the PNA-LNA PCR clamp and Scorpion ARMS methods can detect only known mutations. 48,52e54 Tumor samples used for EGFR mutation analysis were usually obtained from biopsies of primary lung lesions or metastatic lesions. Samples from pleural effusion, circulating tumor cells, and serum or plasma-free DNA could also be used for mutation analysis. 48 ,52,54e58
First-line EGFR-TKI treatment in tumor EGFRmutated NSCLC patients
Recent Phase III randomized clinical trials showed a high level of efficacy of EGFR-TKIs as a first-line treatment for EGFR-mutated NSCLC, compared with platinum-based doublets, in terms of prolongation of PFS, better quality of life, and fewer treatment-induced toxicities (Table 2) .
3,59e62 Thus, first-line treatment with erlotinib or gefitinib is recommended for patients with activating EGFR mutations. 63 The median PFS of EGFR-mutated patients who received EGFR-TKI was approximately 10 months, but 5e6 months if they received platinum-based doublet chemotherapy. However, overall survival was not significantly different between EGFR-mutated patients who received EGFT-TKI and those who received chemotherapy as the first-line treatment. 62,64e67 If the EGFR mutation status is negative or unknown, then cytotoxic chemotherapy is preferred as the first-line treatment.
EGFR-TKI as maintenance therapy after first-line chemotherapy
Two randomized Phase III studies including molecularunselected patients showed that EGFR-TKI was not indicated as an adjuvant or a maintenance therapy in postoperative patients or in stage III patients after chemoradiotherapy. 68, 69 A retrospective study of patients with resected stages IeIII lung adenocarcinomas harboring EGFR exon 19 deletions or exon 21L858R found a trend toward improvement in diseasefree survival among individuals who received EGFR-TKI as an adjuvant therapy compared to those who did not receive it. 70 However, further study is needed to confirm these results. In stage IV NSCLC patients with an unselected or unknown EGFR mutation status, EGFR-TKI was also not indicated for combination with platinum-based doublet chemotherapy followed by EGFR-TKI alone as a maintenance therapy. 26e29 However, whether or not chemotherapy intercalated with EGFR-TKI is useful is still controversial, with conflicting results in Phase II randomized trials 71, 72 and Phase III results still pending. 73 Erlotinib has been tested as a maintenance therapy in a randomized Phase III trial [sequential tarceva in unrectable NSCLC (SATURN)] including 889 molecular-unselected patients with NSCLC who were without disease progression after four cycles of platinum-based doublet chemotherapy. 74 There was a 29% risk reduction in PFS (HR: 0.71, p < 0.0001) favoring erlotinib maintenance treatment, and a survival advantage of 12 months for erlotinib versus 11.1 months for placebo ( p ¼ 0.0088). Among patients with a squamous histology (n ¼ 360), those in the erlotinib group experienced a statistically significantly longer PFS than those receiving placebo (HR: 0.76; 95% CI: 0.60e0.95), but did not experience a statistically significant difference in overall survival (HR: 0.86; 95% CI: 0.68e1.10). Among patients with an adenocarcinoma histology (n ¼ 401), those in the maintenance erlotinib group experienced a statistically significant improvement in PFS (HR: 0.60; 95% CI: 0.48e0.75) and overall survival (HR: 0.77; 95% CI: 061e0.97). EGFR mutation analysis was performed on approximately 40% of patients. Although patients with wild type EGFR had a small PFS benefit from erlotinib (HR: 0.78; p ¼ 0.0185), the most striking difference favoring erlotinib was observed in EGFRmutated patients (HR: 0.10; p<0.0001). Similarly, a Phase III study (Avastin (bevacizumab) and Tarceva (erlotinib) as combined first-line maintenance treatment (ATLAS)) testing bevacizumab with or without erlotinib as a maintenance therapy in patients who received initial platinum-based therapy in combination with bevacizumab and, in the absence of disease progression, found that the bevacizumab plus erlotinib maintenance treatment showed prolongation of PFS (4.8 vs. 3.7 months, p ¼ 0.0012) but not of overall survival. 75 A West Japan Thoracic Oncology Group trial investigated six cycles of platinum-based double-agent therapy compared with three cycles of platinum-based double-agent chemotherapy followed by gefitinib until disease progression. 76 The median number of chemotherapy cycles in both groups was three. The patients in the sequential group experienced a significant prolongation of PFS compared with those in the chemotherapy-alone group, but no statistically significant difference was observed in overall survival. A randomized study performed in China, that was similar to SATURN, showed that PFS was significantly longer with gefitinib (n ¼ 148) than with placebo (n ¼ 148) (median PFS: 4.8 vs. 2.6 months; HR: 0.42; 95% CI: 0.33e0.55; p < 0$0001). 77 However, overall survival was not different. HR for PFS was 0.17 (95% CI: 0.07e0.42) in EGFR-mutated patients and 0.86 (95% CI: 0$48e1.51) in EGFR wild type patients. No benefit in PFS was noted in patients with SCC. 77 
Second-generation, irreversible EGFR-TKIs
Currently, new novel compounds, which bind irreversibly to EGFR-TK, are being tested in clinical studies. 78, 79 These agents, including afatinib (BIBW 2992), PF0299804, and Table 2 Five Phase III randomized trials comparing first-line EGFR-TKI and chemotherapy treatment in clinically or molecularly selected NSCLC patients with EGFR active mutations. Afatinib is an irreversible EGFR and HER2 inhibitor. A Phase II trial of afatinib treatment in 129 EGFR-mutated adenocarcinoma patients showed that 79 (61%) of 129 patients had an objective response to afatinib. Of them, 70 (66%) of 106 patients with the two common activating EGFR mutations (deletion 19 or L858R) had an objective response, as did nine (39%) of 23 patients with less common mutations. 78 Afatinib was compared with placebo in a randomized Phase III trial (LUX-Lung 1) conducted in 585 patients with advanced lung adenocarcinoma pretreated with one or two prior chemotherapies and at least 12 weeks of prior gefitinib or erlotinib. 79 Although there was no significant difference in overall survival (primary end point) between the treatment studies, there was a 2.2-month PFS advantage favoring afatinib (1.1 vs. 3.3 months; p < 0.0001). Preliminary results of a Phase III randomized trial comparing afatinib with pemetrexate plus cisplatin treatment in treatment-naïve tumor EGFR-mutated patients (LUX Lung-3) have recently been published in an annual meeting of ASCO. 81 PF00299804, an irreversible pan-HER inhibitor, was compared with erlotinib in a Phase II randomized trial with 188 patients with NSCLC who had received one or two prior chemotherapies but not EGFR-TKI treatment. PF00299804, compared with erlotinib, showed an improved response rate (17.1% vs. 4.3%; p ¼ 0.008) and median PFS (2.9 vs. 1.9 months, p ¼ 0.017). However, there was an imbalance in the number of EGFR-mutated patients between the two groups, with nearly twice as many patients in the PF00299804 group as in the erlotinib group (20.2% vs. 11.7%). 82 Neratinib is also an irreversible pan-ErbB receptor TKI. A Phase II study of neratinib revealed that the objective response rate was only 3% in 91 previously EGFR-TKI-treated, EGFR-mutated, NSCLC patients with no wild type EGFR who received EGFR-TKI prior to responding to neratinib treatment (n ¼ 48). Also, none of the 28 EGFR-TKI-naïve adenocarcinoma patients with light smoking histories (20 pack-years) responded to treatment. Patients with known T790M also did not respond to neratinib treatment. However, three of four patients with an exon 18 G719X EGFR mutation had a partial response. Thus, although neratinib showed low activity in patients with prior benefit from TKIs and in TKI-naïve patients, it may yet be beneficial for patients with the rare G719X EGFR mutation. 83 
Overcoming acquired EGFR-TKI resistance
Despite the initial success of gefitinib or erlotinib in the treatment of NSCLC with EGFR mutations, most patients will ultimately develop disease progression (acquired resistance to EGFR-TKI). 84 At present, there are several treatment choices if EGFR-TKI treatment fails, including salvage chemotherapy, use of other approved EGFR-TKIs, entering second-line targeted therapy trials, or chemotherapy plus the original EGFR-TKI. Among these options, only salvage chemotherapy is considered as a standard salvage therapy or a better choice. 2 The therapeutic success of reversible EGFR-TKIs in EGFRmutant NSCLC is mainly limited by the development of drug resistance, such as a T790M mutation, which accounts for half of the cases, and by mesenchymal epithelial transition factor (MET) amplification in 5e20% of the patients. 85e87 In a study of 93 patients in whom a rebiopsy was performed after the failure of EGFR-TKI treatment, 58 (62%) patients had a T790M mutation. Patients with the T790M mutation had significantly longer postprogression survival than those with acquired resistance and no T790M mutation. 88 The T790M mutation has also been detected occasionally in tumor specimens from NSCLC patients with no prior exposure to EGFR-TKIs, 39, 88, 89 although the prevalence of this pre-existing T790M can vary depending on the detection method employed. 39 Regarding MET amplification-induced drug resistance, investigators recently found that MET amplification was present in a small fraction of tumor cells prior to EGFR-TKI treatment, and an increased expression of hepatocyte growth factor was found in tumor specimens with acquired resistance to EGFR-TKI. 90 Cell line study also showed that combination treatment with MET and EGFR kinase inhibitors might be beneficial in MET-amplified NSCLC by reducing the selection of drug-resistant clones. 91 These findings support the rationale for an initial combination therapy, specifically in a molecularly defined cohort of patients with evidence of pre-existing MET amplification. 90, 91 In addition to these genetic alterations, loss of insulin-like growth factor (IGF)-binding proteins with activation of IGF1Rb/IRS-1 signaling also drives EGFR-TKI resistance in EGFR wild-type cancer cell lines. 92 Other possible mechanisms included phosphoinositide 3-kinase autoactivation through an Erb3 pathway or loss of PTEN expression, a smallcell lung cancer transformation, and an epithelial to mesenchymal transition. 87,93e95 In conclusion, EGFR mutation is the most common driver oncogene found in Asian NSCLC patients. Every effort should be exercised to ascertain the EGFR mutation status in our patients prior to initiating systemic treatment. First-line treatments with EGFR-TKI, such as gefitinib or erlotinib, should be given to EGFR-mutated stage IV NSCLC patients. First-line platinum-based doublet chemotherapy is the treatment of choice for NSCLC patients with wild-type or unknown EGFR mutation status. For patients with unknown EGFR mutation status, first-line EGFR-TKI treatment could be considered in those with a poor performance status of 3 or 4, because chemotherapy is not an appropriate treatment for these patients. Median PFS of EGFR-TKI is around 10 months, and strategies to overcome acquired resistance to EGFR-TKI are in ongoing development.
